CPMS | NEWSLETTER | ERN
HealthFlex
×
  • Home
  • The Network
    • Who We Are
    • Our Vision, Mission & Aim
    • Structure & Governance
    • Specialised Centres
    • Coordinators
    • Stakeholders & Supporters
    • Informative Materials
  • For Patients
    • Patient Board
    • Find a specialist centre
    • Patient Organisations
    • Patient Resources
    • Cross-border Healthcare
  • Expertise
    • Evaluation
    • Education Programme
    • Guidelines
    • UIMD Registry
    • Subnetworks
    • Work Packages
    • Transversal Activities
    • CPMS Support
    • Resources
  • News & Events
    • News
    • Events
  • Activities
    • Projects
    • Publications
  • Contact Us

COVID-19 Recommendations for all Rare IMD Patients and Caregivers

COVID-19 Recommendations for all Rare IMD Patients and Caregivers
EducationNews

MetabERN Recommendations for all Rare Inherited Metabolic Diseases patients and caregivers about treatment adherence during the COVID-19 emergency

The COVID-19 pandemic is testing the resilience of robust health systems around the world. This may be impacting you in many different ways, such as creating additional anxiety or exacerbating other medical or therapy issues related to your Inherited Metabolic Disease (IMD).  In this difficult period MetabERN underlines the critical importance of sustaining efforts to prevent, diagnose and treat Inherited Metabolic Diseases (IMDs) assuring the continuation of the quality of care provided to you.

To help the entire metabolic community, we have developed some recommendations that aim to support all rare IMD patients and caregivers during the COVID-19 emergency.

Infographic

The Clinical Management Support System (COVID19 CMSS)

The European Commission has started this initiative to support the clinicians and healthcare providers dealing with the care of COVID-19 infected patients, the Clinical Management Support System (COVID19 CMSS) that allows sharing clinical knowledge and expertise among peers.

Based on the European Reference Network System, the COVID19 –CMSS is aiming to allow clinicians to communicate easily with any other colleagues across the EU, the UK and EEA to exchange knowledge and discuss cases, as the gained clinical experience can represent an important contribution which could benefit hundreds of patients and healthcare professionals.

Any healthcare professional involved in complex COVID-19 cases can access the Web Conferencing system and get the support of a dedicated Helpdesk by registering through this link: https://ec.europa.eu/eusurvey/runner/COVID19CENTRES where you will find a detailed description of the system (factsheet) and a privacy statement in compliance with the GDPR.

After to your registration, we will contact you and provide you with the data of all participants and with operational aspects and instructions on the use of the system.

Should you know of any other professional willing to benefit of this Web Conferencing system, please do not hesitate to forward this invitation to your peers.

COVID-19: MetabERN Recommendations for IMD Patients

MetabERN COVID-19 Vaccine Recommendations

The experts of MetabERN recommend that IMD patients get vaccinated against COVID-19 when they are
offered this opportunity.

All IMDs should be considered as a high priority for COVID-19 vaccination. Patients who present a high
risk of acute metabolic decompensation, respiratory or cardiac complications, and frequent
exacerbation induced by infection, such as those with AOA, PM-MD, C-FAO and LSD, should be
vaccinated with the highest priority.
Based on the current evidence, our experts’ advice is to use any vaccine available in the country, with no
particular contraindications for any metabolic disease.

COVID-19 Vaccine Recommendations | Info-graphic

MetabERN Recommendations

MetabERN Recommendations

Q&A

Q&As and National Contact Numbers

National and Disease Specific Recommendations

Čeština

Koronavirus – stanovisko ČAVO

Deutsch

CDG: ERKLÄRUNG ZUM COVID-19-AUSBRUCH

MPS: https://mps-ev.de/aktuell/

PKU: https://www.facebook.com/digpku/

Eesti

CDG: AVALDUS COVID-19 PUHANGU KOHTA

English

AKU: aimAKU-DSAKU-metabERN-COVID19-statement

CDG: STATEMENT ON COVID-19 OUTBREAK

Ketotic Hypoglycemia: COVID-19 Guidelines

IMDs and Coronavirus: Webinar and COVID Webinar Slides

Fabry: Webinar

Español

CDG: DECLARACIÓN SOBRE COVID-19

RECOMENDACIONES EN CASO DE INFECCIÓN POR SARS en Paciente Metabolico

Français

CDG: DÉCLARATION SUR L’ÉPIDÉMIE DE COVID-19

Italiano

COVID-19 e Malattie Ereditarie Metaboliche

Alcaptonuria: Suggerimenti e consigli ai pazienti

CDG: DICHIARAZIONE SULLA PANDEMIA COVID-19

Terapia Enzimatica Sostitutiva: Determinazione AIFA ERT

Piccolo Vademecum in tempo di Coronavirus: Vademecum

Malattia di Fabry: Vademecum

Nederlands

CDG: BETREFFENDE COVID-19 UITBRAAK

Norway

Råd angående koronavirus til pasienter med medfødte stoffskiftesykdommer

Polski

CDG: OŚWIADCZENIE NA TEMAT PANDEMII COVID-19

Português

CDG: COMUNICADO SOBRE A PANDEMIA COVID-19

Slovenský

CDG: STANOVISKO K COVID-19 PANDÉMII

Search

Last News & Events

  • EJP RD workshop – The Blood-Brain Barrier: current research and novel therapeutic crossing approaches
  • Patient representatives for Smith-Lemli-Opitz syndrome are looking for European families
  • Rare disease education in Europe – read the new publication
  • Rare Diseases events under the Czech EU Council Presidency
  • MetabERN Board meeting in Prague, 13-15 October 2022
  • EJP Research Mobility Fellowship is now open
  • First Italian National Meeting on Rare Inherited Metabolic Diseases in Adults
  • IRDiRC Diagnostic Scientific Committee Nomination Call

Activities

  • Publications and Guidelines
  • Unified Registry for Inherited Metabolic Disorders
  • Projects

Disclaimer

MetabERN is a European Reference Network (ERN) approved by the ERN Board of Member States.
The ERNs are co-funded by the European Commission.
For more information about the ERNs and the EU health strategy, please visit ec.europa.eu/health/ern
The content on this website represents the views of the network and is its sole responsibility; it can in no way be taken to reflect the views of the European Commission or any other body of the European Union.

For more information please contact
Prof. Maurizio Scarpa, MD, PhD
MetabERN Coordinator

Newsletter

Sign up to the MetabERN newsletter

Follow us on Twitter

Tweets by @Metab_ERN

Search the website


Copyright ©2017-2021 all rights reserved
Previous Content

Web by EFFIGE 2.0
To provide the best possible service, we use technical, statistical and third-party cookies on this site. Continuing the navigation you consent to use them. Accept Reject Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT